» Articles » PMID: 12019079

Resistance Mechanisms in Clinical Isolates of Candida Albicans

Overview
Specialty Pharmacology
Date 2002 May 23
PMID 12019079
Citations 164
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance to azole antifungals continues to be a significant problem in the common fungal pathogen Candida albicans. Many of the molecular mechanisms of resistance have been defined with matched sets of susceptible and resistant clinical isolates from the same strain. Mechanisms that have been identified include alterations in the gene encoding the target enzyme ERG11 or overexpression of efflux pump genes including CDR1, CDR2, and MDR1. In the present study, a collection of unmatched clinical isolates of C. albicans was analyzed for the known molecular mechanisms of resistance by standard methods. The collection was assembled so that approximately half of the isolates were resistant to azole drugs. Extensive cross-resistance was observed for fluconazole, clotrimazole, itraconazole, and ketoconazole. Northern blotting analyses indicated that overexpression of CDR1 and CDR2 correlates with resistance, suggesting that the two genes may be coregulated. MDR1 overexpression was observed infrequently in some resistant isolates. Overexpression of FLU1, an efflux pump gene related to MDR1, did not correlate with resistance, nor did overexpression of ERG11. Limited analysis of the ERG11 gene sequence identified several point mutations in resistant isolates; these mutations have been described previously. Two of the most common point mutations in ERG11 associated with resistance, D116E and E266D, were tested by restriction fragment length polymorphism analysis of the isolates from this collection. The results indicated that the two mutations occur frequently in different isolates of C. albicans and are not reliably associated with resistance. These analyses emphasize the diversity of mechanisms that result in a phenotype of azole resistance. They suggest that the resistance mechanisms identified in matched sets of susceptible and resistant isolates are not sufficient to explain resistance in a collection of unmatched clinical isolates and that additional mechanisms have yet to be discovered.

Citing Articles

Batzelladine D, a Marine Natural Product, Reverses the Fluconazole Resistance Phenotype Mediated by Transmembrane Transporters in and Interferes with Its Biofilm: An In Vitro and In Silico Study.

Domingos L, de Moraes D, Santos M, Curvelo J, Bayona-Pacheco B, Marquez E Mar Drugs. 2024; 22(11).

PMID: 39590782 PMC: 11595962. DOI: 10.3390/md22110502.


Adaptation of Candida albicans to specific host environments by gain-of-function mutations in transcription factors.

Morschhauser J PLoS Pathog. 2024; 20(11):e1012643.

PMID: 39495716 PMC: 11534201. DOI: 10.1371/journal.ppat.1012643.


Nystatin Encapsulated Nanoliposomes: Potential Anti-infective against Candida Spp. Isolated from Candidiasis Patients.

Asadi M, Toofani-Milani A, Bahman Soufiani K Adv Biomed Res. 2024; 13:56.

PMID: 39411705 PMC: 11478779. DOI: 10.4103/abr.abr_65_23.


Yeast Particle Encapsulation of Azole Fungicides for Enhanced Treatment of Azole-Resistant .

Soto E, Rus F, Ostroff G J Funct Biomater. 2024; 15(8).

PMID: 39194641 PMC: 11355591. DOI: 10.3390/jfb15080203.


Erg251 has complex and pleiotropic effects on sterol composition, azole susceptibility, filamentation, and stress response phenotypes.

Zhou X, Hilk A, Solis N, Pereira De Sa N, Hogan B, Bierbaum T PLoS Pathog. 2024; 20(7):e1012389.

PMID: 39078851 PMC: 11315318. DOI: 10.1371/journal.ppat.1012389.


References
1.
Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W . Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (Reading). 1999; 145 ( Pt 10):2701-2713. DOI: 10.1099/00221287-145-10-2701. View

2.
Perepnikhatka V, FISCHER F, Niimi M, Baker R, Cannon R, Wang Y . Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans. J Bacteriol. 1999; 181(13):4041-9. PMC: 93895. DOI: 10.1128/JB.181.13.4041-4049.1999. View

3.
Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh T . Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. J Clin Microbiol. 2000; 38(4):1563-8. PMC: 86490. DOI: 10.1128/JCM.38.4.1563-1568.2000. View

4.
Lyons C, White T . Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob Agents Chemother. 2000; 44(9):2296-303. PMC: 90061. DOI: 10.1128/AAC.44.9.2296-2303.2000. View

5.
Calabrese D, Bille J, Sanglard D . A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology (Reading). 2000; 146 ( Pt 11):2743-2754. DOI: 10.1099/00221287-146-11-2743. View